Cyanotech Corp.
Cyanotech Corporation produces natural products from microalgae worldwide. Products include BioAstin Hawaiian Astaxanthin for skin, eye, joint, and immune health, and Hawaiian Spirulina Pacifica for energy, immune system, and cardiovascular health. The company also offers contract extraction and research services.
Overview
Strengths
- Price to book ratio (0.21) is lower than the sector mean (5.03).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (62.33).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (10.87%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (27.63).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |